GlassScriptPhysician profile
Mark J Schneider
NPI 1902171085
$3,124.61
in general payments reported to CMS, 2019-2025
21 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $38.64 · 2021: $448 · 2022: $211 · 2023: $704 · 2024: $616 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $601.62 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $464.33 | 2023-2025 | Lifevest |
| Boston Scientific Corporation | $434.73 | 2019-2024 | Watchman Flx |
| Shockwave Medical, INC | $311.77 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $295.26 | 2020-2023 | Repatha |
| Abiomed | $236.00 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $141.65 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $124.98 | 2025 | Uptravi, Opsumit |
| Pfizer INC. | $122.15 | 2022-2025 | |
| Astellas Pharma US INC | $99.99 | 2021 | |
| Novo Nordisk INC | $46.03 | 2024-2025 | Rybelsus, Ozempic |
| Baxter Healthcare | $44.12 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $34.28 | 2025 | Farxiga |
| Esperion Therapeutics, INC. | $24.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $23.61 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $23.42 | 2024 | Arcalyst |
| Cvrx, INC. | $23.27 | 2023 | Barostim Neo System |
| Abbott Laboratories | $21.71 | 2023 | Xience Skypoint |
| Chiesi USA, INC. | $20.00 | 2021 | |
| Cardiva Medical, INC. | $17.68 | 2022 | |
| Merck Sharp & Dohme LLC | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.